Molecular and genetic features of myelodysplastic syndromes

International Journal of Laboratory Hematology

Volumn 34, Issue 3, 2012, Pages 215-222

  Greenberg, P L ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

Molecular biology; Molecular genetics; Myelodysplastic syndromes

Indexed keywords

CYTOGENETICS; GENE MUTATION; HEMATOPOIESIS; HUMAN; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TELOMERE;

APOPTOSIS; CELL CYCLE; CYTOGENETICS; DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENETIC VARIATION; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 84860229279     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2011.01390.x     Document Type: Review

References (59)

1. Adamson D.J., Dawson A., Bennett B., King D.J. & Haites N.E. (1995) p53 mutation in the myelodysplastic syndromes. British Journal Haematology 89, 61-66.
2. Afable M.G., Wlodarski M., Makishima H., Shaik M., Sekeres M.A., Tiu R.V., Kalaycio M., O'Keefe C.L. & Maciejewski J.P. (2011) SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood 117, 6876-6884.
3. Bejar R., Levine R. & Ebert B.L. (2011) Unraveling the molecular pathophysiology of myelodysplastic syndromes. Journal of Clinical Oncology 29, 504-515.
4. Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., Kantarjian H., Raza A., Levine R.L., Neuberg D. & Ebert B.L. (2011) Clinical effect of point mutations in myelodysplastic syndromes. New England Journal of Medicine 364, 2496-2506.
5. Ben-Yehuda D., Krichevsky S., Caspi O., Rund D., Polliack A., Abeliovich D., Zelig O., Yahalom V., Paltiel O., Or R., Peretz T., Ben-Neriah S., Yehuda O. & Rachmilewitz E.A. (1996) Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 88, 4296.
6. Boudard D., Vasselon C., Bertheas M.F., Jaubert J., Mounier C., Reynaud J., Viallet A., Chautard S., Guyotat D. & Campos L. (2002) Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. American Journal of Hematology 70, 115-125.
7. Briatore F., Barrera G., Pizzimenti S., Toaldo C., Casa C.D., Laurora S., Pettazzoni P., Dianzani M.U. & Ferrero D. (2009) Increase of telomerase activity and hTERT expression in myelodysplastic syndromes. Cancer Biology and Therapeutics 8, 883-889.
8. Cilloni D., Gottardi E., Messa F., Fava M., Scaravaglio P., Bertini M., Girotto M., Marinone C., Ferrero D., Gallamini A., Levis A. & Saglio G.Piedmont Study Group on Myelodysplastic Syndromes. (2003) Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. Journal of Clinical Oncology 21, 1988-1995.
9. Czibere A., Burns I., Junge B., Singh R., Kobbe G., Haas R. & Germing U. (2009) Low RPS14 expression is common in myelodysplastic syndromes without 5q-aberration and defines a subgroup of patients with prolonged survival. Haematologica 94, 1453-1455.
10. Davis R.E. & Greenberg P.L. (1998) Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: impact on disease progression. Leukemia Research 22, 767-777.
11. Dicker F., Haferlach C., Sundermann J., Wendland N., Weiss T., Kern W., Haferlach T. & Schnittger S. (2010) Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 24, 1528-1532.
12. Ebert B.L., Pretz J., Bosco J., Chang C.Y., Tamayo P., Galili N., Raza A., Root D.E., Attar E., Ellis S.R. & Golub T.R. (2008) Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 451, 335-339.
13. Figueroa M.E., Skrabanek L., Li Y., Jiemjit A., Fandy T.E., Paietta E., Fernandez H., Tallman M.S., Greally J.M., Carraway H., Licht J.D., Gore S.D. & Melnick A. (2009) MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114, 3448-3458.
14. Gondek L.P., Tiu R., O'Keefe C.L., Sekeres M.A., Theil K.S. & Maciejewski J.P. (2008) Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111, 1534-1542.
15. Greenberg P.L. (2006a) Clinical and prognostic characterization of myelodysplastic syndrome. In: Myelodysplastic Syndromes: Clinical and Biological Advances (ed. P.L. Greenberg ), 1-32. Cambridge University Press, Cambridge, England.
16. Greenberg P.L. (2006b) Pathogenetic mechanisms underlying myelodysplastic syndrome. In: Myelodysplastic Syndromes: Clinical and Biological Advances (ed. P.L. Greenberg ), 63-94. Cambridge University Press, Cambridge, England.
17. Greenberg P., Cox C., Le Beau M.M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G. & Bennett J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079-2088.
18. Greenberg P., Tuechler H., Schanz J., Sole F., Bennett J.M., Garcia-Manero G., Levis A., Malcovati L., Cazzola M., Sanz G., Cermak J., Fonatsch C., Le Beau M., Slovak M., Krieger O., Luebbert M., Magalhaes S., Miyazaki Y., Pfeilstoecker M., Sekeres M., Maciejewski J., Stauder R., Tauro S., van de Loosdrecht A., Germing U., Fenaux P. & Haase D. (2011) Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM). Leukemia Research 35(Suppl 1), S6.
19. Harada H., Harada Y., Niimi H., Kyo T., Kimura A. & Inaba T. (2004) High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103, 2316-2324.
20. Horiike S., Misawa S., Kaneko H., Sasai Y., Kobayashi M., Fujii H., Tanaka S., Yagita M., Abe T., Kashima K. & Taniwaki M. (1999) Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype. Leukemia 13, 1235.
21. Horiike S., Kita-Sasai Y., Nakao M. & Taniwaki M. (2003) Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome. Leukaemia & Lymphoma 44, 915-922.
22. Issa P. (2010) Epigenetic changes in the myelodysplastic syndrome. Hematology/oncology Clinics of North America 24, 317-330.
23. Jädersten M., Saft L., Smith A., Kulasekararaj A., Pomplun S., Göhring G., Hedlund A., Hast R., Schlegelberger B., Porwit A., Hellström-Lindberg E. & Mufti G.J. (2011) TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. Journal of Clinical Oncology 29, 1971-1979.
24. Jankowska A.M., Szpurka H., Tiu R.V., Makishima H., Afable M., Huh J., O'Keefe C.L., Ganetzky R., McDevitt M.A. & Maciejewski J.P. (2009) Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 113, 6403-6410.
25. Kelly L.M. & Gilliland D.G. (2002) Genetics of myeloid leukemias. Annual Review of Genomics &Human Genetics 3, 179-198.
26. Kita-Sasai Y., Horiike S., Misawa S., Kaneko H., Kobayashi M., Nakao M., Nakagawa H., Fujii H. & Taniwaki M. (2001) International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. British Journal Haematology 115, 309-312.
27. Kosmider O., Gelsi-Boyer V., Cheok M., Grabar S., Della-Valle V., Picard F., Viguie′ F., Quesnel B., Beyne-Rauzy O., Solary E., Vey N., Hunault-Berger M., Fenaux P., Mansat-De Mas V., Delabesse E., Guardiola P., Lacombe C., Vainchenker W., Preudhomme C., Dreyfus F., Bernard O.A., Birnbaum D. & Fontenay M. (2009) TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes. Blood 114, 3285-3291.
28. Lange K., Holm L., Vang Nielsen K., Hahn A., Hofmann W., Kreipe H., Schlegelberger B. & Göhring G. (2010) Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes Chromosomes Cancer 49, 260-269.
29. Mallo M., Cervera J., Schanz J., Such E., García-Manero G., Luño E., Steidl C., Espinet B., Vallespí T., Germing U., Blum S., Ohyashiki K., Grau J., Pfeilstöcker M., Hernández J.M., Noesslinger T., Giagounidis A., Aul C., Calasanz M.J., Martín M.L., Valent P., Collado R., Haferlach C., Fonatsch C., Lübbert M., Stauder R., Hildebrandt B., Krieger O., Pedro C., Arenillas L., Sanz M.Á., Valencia A., Florensa L., Sanz G.F., Haase D. & Solé F. (2011) Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 25, 110-120.
30. Mills K., Kohlmann A., Williams P.M., Wieczorek L., Liu W.M., Li R., Wei W., Bowen D.T., Loeffler H., Hernandez J.M., Hofmann W.K. & Haferlach T. (2009) Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 114, 1063-1072.
31. Mori N., Hidai H., Yokota J., Okada M., Motoji T., Oshimi K. & Mizoguchi H. (1995) Mutations of the p53 gene in myelodysplastic syndrome and overt leukemia. Leukemia Research 19, 869.
32. Nakao M., Horiike S., Fukushima-Nakase Y., Nishimura M., Fujita Y., Taniwaki M. & Okuda T. (2004) Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome. British Journal Haematology 125, 709-719.
33. Neubauer A., Greenberg P., Negrin R., Ginzton N. & Liu E. (1994) Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. Leukemia 8, 638.
34. Ohyashiki J.H., Iwama H., Yahata N., Ando K., Hayashi S., Shay J.W. & Ohyashiki K. (1999) Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clinical Cancer Research 5, 1155-1160.
35. Olney H.J. & Le Beau M.M. (2006) Cytogenetic abnormalities. In: Myelodysplastic Syndromes: Clinical and Biological Advances (ed. P.L. Greenberg ), 95-128. Cambridge University Press, Cambridge, England.
36. Padua R.A., Guinn B., Al-Sabah A.I., Smith M., Taylor C., Pettersson T., Ridge S., Carter G., White D., Oscier D., Chevret S. & West R. (1998) RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 12, 887-892.
37. Papaemmanuil E., Cazzola M., Boultwood J., Malcovati L., Vyas P., Bowen D., Pellagatti A., Wainscoat J.S., Hellstrom-Lindberg E., Gambacorti-Passerini C., Godfrey A.L., Rapado I., Cvejic A., Rance R., McGee C., Ellis P., Mudie L.J., Stephens P.J., McLaren S., Massie C.E., Tarpey P.S., Varela I., Nik-Zainal S., Davies H.R., Shlien A., Jones D., Raine K., Hinton J., Butler A.P., Teague J.W., Baxter E.J., Score J., Galli A., Della Porta M.G., Travaglino E., Groves M., Tauro S., Munshi N.C., Anderson K.C., El-Naggar A., Fischer A., Mustonen V., Warren A.J., Cross N.C., Green A.R., Futreal P.A., Stratton M.R. & Campbell P.J. (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. New England Journal of Medicine 365, 1384-1395.
38. Paquette R.L., Landaw E., Pierre R.V., Kahan J., Lübbert M., Lazcano O., Isaac G., McCormick F. & Koeffler H.P. (1993) N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 82, 590-599.
39. Parker J.E., Mufti G., Rasool F., Mijovic A., Devereux S. & Pagliuca A. (2000) The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 96, 3932-3938.
40. Pellagatti A., Cazzola M., Giagounidis A., Perry J., Malcovati L., Della Porta M.G., Jädersten M., Killick S., Verma A., Norbury C.J., Hellström-Lindberg E., Wainscoat J.S. & Boultwood J. (2010a) Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 24, 756-764.
41. Pellagatti A., Marafioti T., Paterson J.C., Barlow J.L., Drynan L.F., Giagounidis A., Pileri S.A., Cazzola M., McKenzie A.N., Wainscoat J.S. & Boultwood J. (2010b) Induction of p53 and up-regulation of the p53 pathway in the human 5q-syndrome. Blood 115, 2721-2723.
42. Pellagatti A., Cazzola M., Giagounidis A., Perry J., Malcovati L., Della Porta M., Jadersten M., Killick S., Vyas P., Hellstrom-Lindberg E., Wainscoat J. & Boultwood J. (2011) Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome. British Journal of Haematology 155, 272-274.
43. Quesnel B., Guillerm G., Vereecque R., Wattel E., Preudhomme C., Bauters F., Vanrumbeke M. & Fenaux P. (1998) Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91, 2985-2990.
44. Rajapaksa R., Ginzton N., Rott L. & Greenberg P.L. (1996) Altered oncogene expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88, 4275-4287.
45. Ridge S.A., Worwood M., Oscier D., Jacobs A. & Padua RA. (1990) FMS mutations in myelodysplastic, leukemic, and normal subjects. Proceedings of the National Academy of Sciences of the United States of America 87, 1377.
46. Rocquain J., Carbuccia N., Trouplin V., Raynaud S., Murati A., Nezri M., Tadrist Z., Olschwang S., Vey N., Birnbaum D., Gelsi-Boyer V. & Mozziconacci M.J. (2010) Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. Biomed Central Cancer 10, 401-408.
47. Schanz J., Tuechler H., Sole F., Mallo M., Luno E., Cervera J., Granada I., Hildebrandt B., Slovak M., Ohyashiki K., Steidl C., Fonatsch C., Pfeilstöcker M., Nösslinger T., Valent P., Giagounidis A., Aul C., Lübbert M., Stauder R., Krieger O., Garcia-Manero G., Faderl S., Pierce S., Le Beau M.M., Bennett J., Greenberg P., Germing U. & Haase D (2012) A new comprehensive cytogenetic scoring system for primary myelodysplastic syndromes and oligoblastic AML following MDS derived from an international database merge. J Clin Oncology, in press.
48. Shih L.Y., Huang C., Wang P.N., Wu J.H., Lin T.L., Dunn P. & Kuo M.C. (2004a) Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 18, 466-475.
49. Shih L.Y., Lin T., Wang P.N., Wu J.H., Dunn P., Kuo M.C. & Huang C.F. (2004b) Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Cancer 101, 989-998.
50. Sridhar K., Ross D., Tibshirani R., Butte A. & Greenberg P.L. (2009) Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Blood 114, 4847-4858.
51. Starczynowski D.T., Kuchenbauer F., Argiropoulos B., Sung S., Morin R., Muranyi A., Hirst M., Hogge D., Marra M., Wells R.A., Buckstein R., Lam W., Humphries R.K. & Karsan A. (2010) Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nature Medicine 16, 49-58.
52. Sugimoto K., Hirano N., Toyoshima H., Chiba S., Mano H., Takaku F., Yazaki Y. & Hirai H. (1993) Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 81, 3022.
53. Tang J.L., Tien H., Lin M.T., Chen P.J. & Chen Y.C. (1998) p53 mutation in advanced stage of primary myelodysplastic syndrome. Anticancer Research 18, 3757.
54. Thol F., Friesen I., Damm F., Yun H., Weissinger E.M., Krauter J., Wagner K., Chaturvedi A., Sharma A., Wichmann M., Göhring G., Schumann C., Bug G., Ottmann O., Hofmann W.K., Schlegelberger B., Heuser M. & Ganser A. (2011) Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. Journal of Clinical Oncology 29, 2499-2506.
55. Tobal K., Pagliuca A., Bhatt B., Bailey N., Layton D. & Mufti G.J. (1990) Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 4, 486.
56. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., Harris N.L., Le Beau M.M., Hellström-Lindberg E., Tefferi A. & Bloomfield C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937-951.
57. Walter M.J., Ding L., Shen D., Shao J., Grillot M., McLellan M., Fulton R., Schmidt H., Kalicki-Veizer J., O'Laughlin M., Kandoth C., Baty J., Westervelt P., DiPersio J.F., Mardis E.R., Wilson R.K., Ley T.J. & Graubert T.A. (2011) Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25, 1153-1158.
58. Wattel E., Preudhomme C., Hecquet B., Anrumbeke M., Quesnel B., Dervite I., Morel P. & Fenaux P. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84, 3148.
59. Yoshida K., Masashi Sanada M., Yuichi Shiraishi Y., Nowak D., Nagata Y., Yamamoto R., Sato Y., Sato-Otsubo A., Kon A., Nagasaki M., Chalkidis G., Suzuki Y., Shiosaka M., Kawahata R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M., Ishiyama K., Mori H., Nolte F., Hofmann W.K., Miyawaki S., Sugano S., Haferlach C., Koeffler H.P., Shih L.Y., Haferlach T., Chiba S., Nakauchi H., Miyano S. & Ogawa S. (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64-69.